SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

1/31/24 2:08:28 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MIRM alert in real time by email

SC 13G 1 us6047491013_013124.txt us6047491013_013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Mirum Pharmaceuticals, Inc -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 604749101 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 604749101 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 2494254 (6) Shared voting power 0 (7) Sole dispositive power 2532642 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 2532642 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 5.4% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- Mirum Pharmaceuticals, Inc Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 950 TOWER LANE, SUITE 1050FOSTER CITY CA 94404 foster city CA 94404 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 2532642 Percent of class 5.4% Number of shares as to which such person has: Sole power to vote or to direct the vote 2494254 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 2532642 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Mirum Pharmaceuticals, Inc. No one person's interest in the common stock of Mirum Pharmaceuticals, Inc is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 31, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary BlackRock Advisors, LLC Aperio Group, LLC BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Fund Managers Ltd BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary

Get the next $MIRM alert in real time by email

Recent Analyst Ratings for

$MIRM

Date	Price Target	Rating	Analyst
9/24/2025	$95.00	Buy	TD Cowen
8/11/2025	$89.00	Buy	Stifel
5/19/2025	$73.00	Buy	H.C. Wainwright
4/17/2024	$48.00	Buy	Stifel
12/18/2023	$60.00 → $58.00	Buy	H.C. Wainwright
11/20/2023	$37.00	Overweight	Analyst
11/13/2023	$60.00	Overweight	Morgan Stanley
10/24/2023	$50.00	Overweight	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

1/31/24 2:08:28 PM ET

$MIRM

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MIRM alert in real time by email

Recent Analyst Ratings for

$MIRM

Date	Price Target	Rating	Analyst
9/24/2025	$95.00	Buy	TD Cowen
8/11/2025	$89.00	Buy	Stifel
5/19/2025	$73.00	Buy	H.C. Wainwright
4/17/2024	$48.00	Buy	Stifel
12/18/2023	$60.00 → $58.00	Buy	H.C. Wainwright
11/20/2023	$37.00	Overweight	Analyst
11/13/2023	$60.00	Overweight	Morgan Stanley
10/24/2023	$50.00	Overweight	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MIRM

SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MIRM

$MIRM
Analyst Ratings

TD Cowen initiated coverage on Mirum Pharmaceuticals with a new price target

Stifel resumed coverage on Mirum Pharmaceuticals with a new price target

H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

$MIRM
Insider Purchases

Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

$MIRM
SEC Filings

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

SEC Form 8-K filed by Mirum Pharmaceuticals Inc.

$MIRM
FDA approvals

February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

$MIRM
Insider Trading

$MIRM
Press Releases

CHIEF EXECUTIVE OFFICER Peetz Christopher gifted 21,070 shares (SEC Form 4)

Director Ramasastry Saira exercised 5,000 shares at a strike of $23.51 and sold $400,000 worth of shares (5,000 units at $80.00) (SEC Form 4)

Director Grey Michael G exercised 50,000 shares at a strike of $2.94 and sold $3,900,000 worth of shares (50,000 units at $78.00) (SEC Form 4)

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

$MIRM
Financials

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

$MIRM
Leadership Updates

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

$MIRM
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MIRM

SEC Form SC 13G filed by Mirum Pharmaceuticals Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MIRM

$MIRM Analyst Ratings

TD Cowen initiated coverage on Mirum Pharmaceuticals with a new price target

Stifel resumed coverage on Mirum Pharmaceuticals with a new price target

H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

$MIRM Insider Purchases

Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

$MIRM SEC Filings

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

SEC Form 144 filed by Mirum Pharmaceuticals Inc.

SEC Form 8-K filed by Mirum Pharmaceuticals Inc.

$MIRM FDA approvals

February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

$MIRM Insider Trading

$MIRM Press Releases

CHIEF EXECUTIVE OFFICER Peetz Christopher gifted 21,070 shares (SEC Form 4)

Director Ramasastry Saira exercised 5,000 shares at a strike of $23.51 and sold $400,000 worth of shares (5,000 units at $80.00) (SEC Form 4)

Director Grey Michael G exercised 50,000 shares at a strike of $2.94 and sold $3,900,000 worth of shares (50,000 units at $78.00) (SEC Form 4)

Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX

$MIRM Financials

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

$MIRM Leadership Updates

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

$MIRM Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

Recent Analyst Ratings for
$MIRM

Recent Analyst Ratings for
$MIRM

$MIRM
Analyst Ratings

$MIRM
Insider Purchases

$MIRM
SEC Filings

$MIRM
FDA approvals

$MIRM
Insider Trading

$MIRM
Press Releases

$MIRM
Financials

$MIRM
Leadership Updates

$MIRM
Large Ownership Changes